1. Home
  2. CNOB vs CAPR Comparison

CNOB vs CAPR Comparison

Compare CNOB & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ConnectOne Bancorp Inc.

CNOB

ConnectOne Bancorp Inc.

HOLD

Current Price

$29.79

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$28.92

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNOB
CAPR
Founded
1982
2005
Country
United States
United States
Employees
756
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
CNOB
CAPR
Price
$29.79
$28.92
Analyst Decision
Buy
Strong Buy
Analyst Count
4
8
Target Price
$31.25
$44.63
AVG Volume (30 Days)
301.8K
1.0M
Earning Date
04-23-2026
05-12-2026
Dividend Yield
2.48%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$42.85
N/A
Revenue Next Year
$7.27
$3.31
P/E Ratio
$17.02
N/A
Revenue Growth
N/A
N/A
52 Week Low
$21.82
$4.30
52 Week High
$30.65
$40.37

Technical Indicators

Market Signals
Indicator
CNOB
CAPR
Relative Strength Index (RSI) 57.91 42.73
Support Level $24.76 $28.45
Resistance Level $30.65 $30.06
Average True Range (ATR) 0.76 2.02
MACD -0.12 -0.62
Stochastic Oscillator 69.53 30.00

Price Performance

Historical Comparison
CNOB
CAPR

About CNOB ConnectOne Bancorp Inc.

ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets, and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental, and consumer wages.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: